Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
49 hedge funds and large institutions have $463M invested in Crinetics Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 49 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
67.3% more ownership
Funds ownership: 0% → 67.3% (+67%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$113M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$80.7M |
| 3 |
PA
Perceptive Advisors
New York
|
+$76.8M |
| 4 |
O
OrbiMed
New York
|
+$56.8M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$50.5M |
Top Sellers
CRNX Hedge Fund Activity: Q3 2018 in Review
49 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q3 2018, worth a combined $463M.
Buyers outnumbered sellers: 49 funds opened new CRNX positions and 0 closed out — a net gain of 49 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $113M.
- 49 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $463M of Crinetics Pharmaceuticals stock for Q3 2018.
- 49 funds opened new Crinetics Pharmaceuticals positions in Q3 2018 and 0 closed out, a net change of +49 holders.
- The largest Crinetics Pharmaceuticals buyer in Q3 2018 was Vivo Capital, an estimated $113M added.
Based on aggregated 13F filings for Q3 2018.